Harvard Business Review October 16, 2020
When it comes to leveraging AI, more than 80% of European pharma executives believe that Europe is behind the curve in general — and that European pharma is further behind than most other big-data industries. These are among the findings of a recent survey INSEAD conducted in partnership with Early Metrics (a European startup-rating agency) and Agalio, a Paris-based consulting firm.
Many observers blame Europe’s tough laws regarding data privacy, which are more stringent than those in the United States and China. But our survey suggests that regulation isn’t the problem. Rather, it’s a disconnect between private and public health systems, which makes it difficult for AI programmers to access enough data with which to train their algorithms.
In...
Today's Sponsors
Today's Sponsor